Klassen Preston

President & Head of R & D at Regulus Therapeutics Inc.; President & CEO at Metacrine, Inc.; EVP and CMO at ARENA PHARMACEUTICALS INC, and 1 more

Sold, on record
$1.7M
Dollars the filings state
Form 4 sales
6
Latest Jan 13, 2025
Form 144 notices
0
Proposed sales
Companies
4
Filed as an executive or holder

Companies

Sales by reason

0
Routine
0
Plan not stated
0
No plan
0
Unusual
Stacked: routine sales under a plan, sales whose filing does not state a plan, sales with no plan, and unusual sales.

Form 4 sales per month, last 12 months.

Sales chart range

Sales by company

Shares sold, every Form 4 sale on record.

Timeline

  1. 1 Form 4 sale Orexigen Therapeutics, Inc.Unusual
    May 28, 2013 2013

    Sold 28,771 shares at $7.21 ($207k)

    Klassen Preston, SVP, Head Global Development

    Sold 100% of holdings ($207k position)0 shares leftFirst sale on recordFiling

  2. 2 Form 4 sale Orexigen Therapeutics, Inc.Unusual
    Jul 25, 2013 +58 days

    Sold 71,229 shares at $7.16 ($510k)

    Klassen Preston, SVP, Head Global Development

    Sold 100% of holdings ($510k position)0 shares leftFiling

  3. 3 Form 4 sale ARENA PHARMACEUTICALS INCUnusual
    Jan 8, 2019 +1993 days

    Sold 19,000 shares at $42.06 ($799k)

    Klassen Preston, EVP and CMO

    Sold 100% of holdings ($799k position)0 shares leftFirst sale on recordFiling

  4. 4 Form 4 sale Metacrine, Inc.Plan not stated
    Apr 19, 2022 +1197 days

    Sold 44,748 shares at $0.50 ($22k)

    Klassen Preston, President & CEO

    Sold 4.6% of holdings ($484k position)922,510 shares leftFirst sale on recordFiling

  5. 5 Form 4 sale Metacrine, Inc.Unusual
    Jan 26, 2023 +282 days

    Sold 380,605 shares at $0.41 ($156k)

    Klassen Preston, President & CEO

    Sold 41.3% of holdings ($378k position)541,905 shares leftFiling

  6. 6 Form 4 sale Regulus Therapeutics Inc.Routine
    Jan 13, 2025 +718 days

    Sold 31,445 shares at $1.26 ($40k)

    Klassen Preston, President & Head of R & D

    10b5-1 planSold 46.6% of holdings ($85k position)36,055 shares leftFirst sale on recordFiling

Every transaction

Loading transactions…

Sales and notices (6)

Form 144 notices and Form 4 sales by Klassen Preston
Source
Jan 13, 2025Jan 15, 2025Regulus Therapeutics Inc.President & Head of R & DForm 4 sale31,445$40k46.6%RoutineSEC
Jan 26, 2023Jan 27, 2023Metacrine, Inc.President & CEOForm 4 sale380,605$156k41.3%UnusualSEC
Apr 19, 2022Apr 20, 2022Metacrine, Inc.President & CEOForm 4 sale44,748$22k4.6%Plan not statedSEC
Jan 8, 2019Jan 8, 2019ARENA PHARMACEUTICALS INCEVP and CMOForm 4 sale19,000$799k100.0%UnusualSEC
Jul 25, 2013Jul 29, 2013Orexigen Therapeutics, Inc.SVP, Head Global DevelopmentForm 4 sale71,229$510k100.0%UnusualSEC
May 28, 2013May 30, 2013Orexigen Therapeutics, Inc.SVP, Head Global DevelopmentForm 4 sale28,771$207k100.0%UnusualSEC